Pharmacological Prevention and Termination of Focal Atrial Fibrillation.
Annerie M. E. Moers,Benjamin J. Scherlag,Guodong Niu,Zhibing Lu,Muhammad Ghias,Ralph Lazzara,Warren M. Jackman,Sunny S. Po
DOI: https://doi.org/10.1093/europace/eur301
2011-01-01
Abstract:Aims Patients undergo ablation for focal atrial fibrillation (AF) as a result of failure of anti-arrhythmic drugs. Our basic studies have implicated cholinergic and adrenergic neurotransmitter release as the underlying mechanism for focal AF. Therefore, we tested the efficacy of a combination of sodium channel-blocking agents with additional vagolytic properties and a -blocker to terminate and prevent focal AF.Methods and results In 18 Na-pentobarbital-anaesthetized dogs, after a right or left thoracotomy, acetylcholine (Ach, 0.5 cc, 100 mM) was injected into a fat pad containing ganglionated plexi (GP) or applied on an atrial appendage (AA) to induce focal firing at the pulmonary veins (PVs) or AA, respectively. Disopyramide (24 mg/kg, n 6) or quinidine (36 mg/kg, n 12) combined with esmolol or propranolol (1 mg/kg, n 13 and 5, respectively) were slowly injected to terminate (Group I, n 12) or prevent (Group II, n 6) Ach-induced sustained focal AF. In another four dogs, only the sodium channel-blocking agents with additional vagolytic properties or only the -blocker was injected prior to or after the initiation of focal AF. At baseline, the mean duration of AF induced by Ach was 26 4 min. Group I: After drugs, Ach-induced AF duration was 3 1 min (P 0.001). Group II: Prior to drugs, Ach-induced AF lasted for 19 3 min. With the drug combination the duration of Ach-induced AF, decreased to 6 1/min, P 0.001. Either quinidine or propranolol alone did not change the duration of Ach-induced AF, mean 25 10 min compared with Ach alone, 28 16 min, P 0.2.Conclusions Type IA (cholinergic antagonist) plus Type II (-adrenergic antagonist) provides significant prevention and suppression of focal AF arising at PV and non-PV sites.